Logo image of TEAF

TORTOISE SUST&SOCIAL IMP TER (TEAF) Stock Price, Quote, News and Overview

NYSE:TEAF - New York Stock Exchange, Inc. - US27901F1093 - Currency: USD

12.2  +0.01 (+0.12%)

After market: 12.15 -0.05 (-0.41%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023
Revenue
YoY % growth
TEAF revenue by date.TEAF revenue by date.
11.79M
0.26%
10.85M
-7.97%
10.743M
-0.98%
EBITDA
YoY % growth
TEAF ebitda by date.TEAF ebitda by date.
N/AN/AN/A
EBIT
YoY % growth
TEAF ebit by date.TEAF ebit by date.
7.54M
-2.33%
6.56M
-13.00%
6.862M
4.61%
Operating Margin
TEAF operating margin by date.TEAF operating margin by date.
63.95%60.46%63.88%
EPS
YoY % growth
TEAF eps by date.TEAF eps by date.
N/AN/AN/A

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
TEAF Yearly EPS VS EstimatesTEAF Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth
5.743M
-1.89%
%
Q2 2023
Q2Q % growth
5M
0.14%
%
Q4 2022
Q2Q % growth
5.853M
-8.77%
%
Q2 2022
Q2Q % growth
4.993M
-7.15%
%
Q4 2021
Q2Q % growth
6.416M
362.94%
%
Q2 2021
Q2Q % growth
5.378M
-36.88%
%
Q4 2020
Q2Q % growth
-2.44M
-207.02%
%
Q3 2020
Q2Q % growth
3.24M
9.83%
%
TEAF Yearly Revenue VS EstimatesTEAF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A N/A N/A
RevenueN/A N/A N/A N/A